r-metHuLeptin
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Energy Deficiency Due to Short-term Fasting
Conditions
Energy Deficiency Due to Short-term Fasting
Trial Timeline
Feb 1, 2001 → Dec 1, 2016
NCT ID
NCT00140205About r-metHuLeptin
r-metHuLeptin is a phase 1 stage product being developed by Amgen for Energy Deficiency Due to Short-term Fasting. The current trial status is completed. This product is registered under clinical trial identifier NCT00140205. Target conditions include Energy Deficiency Due to Short-term Fasting.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00140231 | Phase 1/2 | Completed |
| NCT00140205 | Phase 1 | Completed |
Competing Products
1 competing product in Energy Deficiency Due to Short-term Fasting
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Caffeine + Placebo | Bayer | Approved | 82 |